Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab pilot study of angiogenic factor expression during neoadjuvant chemoradiation for esophageal adenocarcinoma
2013-002563-25Phase 2Active
- Sponsor
- VU University Medical Centre
- Start
- Sep 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of bevacizumab in esophageal adenocarcinoma (EAC) and esophageal cancer (2 arms), sponsored by VU University Medical Centre. Primary endpoints: Alteration of VEGF mRNA expression in tumor tissue, VEGFR phosphorylation activity in bevacizumab-treated cohort and 1 more. Started Sep 2013; status: active.
02
Drugs
bevacizumab
03
Conditions
esophageal adenocarcinoma (EAC)esophageal cancer
Beyond the preview
Go deeper on 2013-002563-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002563-25.